Log In
BCIQ
Print this Print this
 

Xyzal, levocetirizine

Also known as: Xusal

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionSingle isomer of cetirizine
Molecular Target Histamine H1 receptor (HRH1)
Mechanism of ActionHistamine H1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsTreat allergy symptoms including seasonal and perennial allergic rhinitis (PAR) and chronic idiopathic urticaria (CIU); Treat persistent allergic rhinitis (PER)
Regulatory Designation
PartnerGlaxoSmithKline plc;
Sanofi;
UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$684.1M

$684.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/26/2009

$684.1M

$684.1M

0

Get a free BioCentury trial today